Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 200233, Shanghai, People's Republic of China.
Endocrine. 2019 Jun;64(3):622-631. doi: 10.1007/s12020-019-01878-0. Epub 2019 Mar 2.
The purpose of this study was using next-generation sequencing technique to explore the potential association between germline variants of 14 targeted genes and papillary thyroid carcinoma (PTC) predisposition as well as disease progression.
In all, 516 subjects were enrolled in this study including 416 PTC patients and 100 healthy controls. PTC patients were divided into distant metastasis group and non-distant metastasis group. Patients in distant metastasis group were further divided into radioiodine-refractory PTC (RR-PTC) and non-RR-PTC depending on their response to radioiodine therapy. Genomic DNA was extracted from peripheral blood sample and MiSeq Benchtop Sequencer was used for sequencing.
We found rs11246050 in NLRP6 (dominant model, OR/95% CI: 2.028/1.091-3.769, p = 0.025), rs2286742 and rs3740530 in HABP2 (recessive model, OR/95% CI: 9.644/1.307-71.16, p = 0.026 and 3.989/1.413-11.26, p = 0.009), rs2736098 in TERT (recessive model, OR/95% CI: 2.322/1.028-5.242. p = 0.042) and rs62054619 in GAS8-AS1 (recessive model, OR/95% CI: 2.219/1.067-4.617, p = 0.033) were associated with the risk of PTC. rs1137282 in KRAS (dominant model, OR/95% CI: 0.5430/0.3192-0.9236, p = 0.024), rs1347591 and rs4461062 in NUP93 (dominant model, OR/95% CI: 0.6121/0.4128-0.9076, p = 0.015 and 0.6156/0.4157-0.9117, p = 0.015) were associated with low risk of distant metastatic disease in PTC patients. rs33954691 in TERT was associated with the risk of RR-PTC under dominant model (OR/95% CI: 3.161/1.596-6.262).
Germline variants of related genes could be associated with the susceptibility of PTC as well as disease progression (distant metastasis and radioiodine-refractory status). However, these results must be further verified and the potential biological functions of these germline variants in the pathogenesis of PTC remain to be determined in future studies.
本研究旨在使用下一代测序技术探讨 14 个靶向基因的种系变异与甲状腺乳头状癌(PTC)易感性及疾病进展之间的潜在关联。
共纳入 516 例受试者,包括 416 例 PTC 患者和 100 例健康对照。将 PTC 患者分为远处转移组和非远处转移组。远处转移组患者根据对放射性碘治疗的反应进一步分为放射性碘难治性 PTC(RR-PTC)和非 RR-PTC。从外周血样本中提取基因组 DNA,并使用 MiSeq Benchtop Sequencer 进行测序。
我们发现 NLRP6 中的 rs11246050(显性模型,OR/95%CI:2.028/1.091-3.769,p=0.025)、HABP2 中的 rs2286742 和 rs3740530(隐性模型,OR/95%CI:9.644/1.307-71.16,p=0.026 和 3.989/1.413-11.26,p=0.009)、TERT 中的 rs2736098(隐性模型,OR/95%CI:2.322/1.028-5.242,p=0.042)和 GAS8-AS1 中的 rs62054619(隐性模型,OR/95%CI:2.219/1.067-4.617,p=0.033)与 PTC 风险相关。KRAS 中的 rs1137282(显性模型,OR/95%CI:0.5430/0.3192-0.9236,p=0.024)、NUP93 中的 rs1347591 和 rs4461062(显性模型,OR/95%CI:0.6121/0.4128-0.9076,p=0.015 和 0.6156/0.4157-0.9117,p=0.015)与 PTC 患者远处转移性疾病低风险相关。TERT 中的 rs33954691 与 RR-PTC 的显性模型相关(OR/95%CI:3.161/1.596-6.262)。
相关基因的种系变异与 PTC 的易感性和疾病进展(远处转移和放射性碘难治性状态)有关。然而,这些结果必须进一步验证,并且这些种系变异在 PTC 发病机制中的潜在生物学功能仍有待在未来的研究中确定。